1. GriffithGH, OwenGM, KirkmanS, et al.Measurement of the rate of gastric emptying using chromium‐51. Lancet1966;1:1244. CrossRef

2. ZiessmanHA, O'MalleyJP, ThrallJH. The Requisites, Nuclear Medicine. 4th ed. Phildelphia: Elsevier Saunders; 2014.

3. ZiessmanHA. Acute cholecystitis, biliary obstruction, biliary extravasation. Semin Nucl Med2003;33:279. CrossRef

4. WeissmannHS, FrankMS, BersteinLH, et al.Rapid and accurate diagnosis of acute cholecystitis with 99mTc‐IDA cholescintigraphy. Am J Roentgenol1979;132:523. CrossRef

5. KimCK, KevinKM, JuweidM, et al.Cholescintigraphy in the diagnosis of acute cholecystisits: morphine augmentation is superior to delayed imaging. J Nucl Med1993;34:1866.

6. ChenPF, NimeriA, PhamQH, et al.The clinical diagnosis of chronic acalculous cholecystitis. Surgery2001;130:578. CrossRef

7. ZiessmanHA. Functional hepatobiliary disease: chronic acalculous gallbladder disease and chronic acalculous biliary disease. Semin Nucl Med2006;36:119. CrossRef

8. YapL, WycherleyAG, MorphettAD, et al.Acalculous biliary pain: cholecystectomy alleviates symptoms in patients with abnormal cholescintigraphy. Gastroenterology1991;101:786.

9. ZiessmanHA, FaheyFH, HixsonDJ. Calculation of a gallbladder ejection fraction: advantage of continuous sincalide infusion over the three‐minute infusion method. J Nucl Med1992;33:537.

10. ZiessmanHA, MunzLR, AgarwalAK, et al.Normal values for sincalide cholescintigraphy. Comparison of two methods. Radiology1992;33:537.

11. ZiessmanHA, TulchinskyM, LavelyWC, et al.Sincalide‐stimulated cholescintigraphy: a multicenter investigation to determine optimal methodology and gallbladder ejection fraction normal values. J Nucl Med2010;51:229. CrossRef

12. DibaiseJK, RichmondBK, ZiessmanHA, et al.Cholecystokinin‐cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. Clin Gastroenterol Hepatol2011;9:376. CrossRef

13. SmytheA, MajeedAW, FitzhenryM, et al.A requiem for the cholecystokinin provocation test?Gut1998;43:571. CrossRef

14. ZiessmanHA. Cholecystokinin cholescintigraphy: victim of its own Success?J Nucl Med1999;40:2038.

15. LeeAW, RamMD, ShihW‐J, et al.Technetium‐99m BIDA biliary scintigraphy in the evaluation of the jaundiced patient. J Nucl Med1986;27:1407.

16. LecklitnerML, AustinAR, BenedettoAR, et al.Positive predictive value of cholescintigraphy in common bile duct obstruction. J Nucl Med1986;27:1403.

17. ZemanRK, LeeC, JaffeMH, et al.Hepatobiliary scintigraphy and sonography in early biliary obstruction. Radiology1984;153:793. CrossRef

18. ZemanRK, BurrellMI, DobbinsJ, et al.Postcholecystectomy syndrome: evaluation using biliary scintigraphy and endoscopic retrograde cholangiopancreatography. Radiology1985;156:787. CrossRef

19. CorazziariE, CicalaM, ScopinaroF, et al.Scintigraphic assessment of SO dysfunction. Gut2003;52:1655. CrossRef

20. SostreS, KallooAN, SPieglerEJ, et al.A noninvasive test of sphincter of Oddi dysfunction in postcholecystectomy patients. The scintigraphic score. J Nucl Med1992;33:1216.

21. WeissmannHS, GliedmanML, WilkPJ, et al.Evaluation of the postoperative patient with 99mTc‐IDA cholescintigraphy. Semin Nucl Med1982;12:27. CrossRef

22. ZiessmanHA, SilvermanPM, FaheyFH, et al.Improved detection of liver hemangiomas with high resolution SPECT. J Nucl Med1991;32:2086.

23. MarianiG, BoniG, BarrecaM, et al.Radionuclide gastroesopageal motor studies. J Nucl Med2004;45:1004.

24. TatschK, VoderholzerW, WeissMJ, et al.Reappraisal of quantitative sophageal scintigraphy by optimizing results with ROC analyses. J Nucl Med1996;1799.

25. ParkmanHP, MaurerAH, CarolineDF, et al.Optimal evalution of patients with nonobstrutive esophageal dysphagia manometry, scintigraphy, or videoesophagography. Dig Dis Sci1996;41:1355. CrossRef

26. HollowayRH, LangeRC, PlankeyMW, et al.Detection of esophageal motor disorders by radionuclide transit studies. A reappraisal. Dig Dis Sci1989;34:905. CrossRef

27. ShaySS, EggliD, JohnsonLF. Simultaneous esophageal pH monitoring and scintigraphy during the postprandial period in patients with severe reflux esophageitis. Dig Dis Sci1991;36:558. CrossRef

28. ZiessmanHA, FaheyFH, AtkinsFB, et al.Standardization and quantification of radionuclide solid gastric emptying studies. J Nucl Med2004;45:760.

29. AbellTL, CamilleriM, DonohoeK, et al.Consensus recommendations for gastric emptying scintigraphy. A Joint Report of the Society of Nuclear Medicine and the American Neurogastroenterology and Motility Society. Am J Gastroenterol2008;103:753. CrossRef

30. TougasG, EakerEY, AbellTL, et al.Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol2000;95:1456. CrossRef

31. ThomfordeGM, CamilleriM, PhillipsSF, et al.Evaluation of an inexpensive screening scintigraphic test of gastric emptying. J Nucl Med1995;36:93.

32. GuoJ‐P, MaurerAH, FisherRS, et al.Extending gastric emptying scintigraphy from 2 to 4 hours detects more patients with gastroparesis. Dig Dis Sci2001;46:24. CrossRef

33. ZiessmanHA, GoetzeS, BontaD, et al.Experience with a new standardized 4‐hr gastric emptying protocol. J Nucl Med2007;48:568. CrossRef

34. ZiessmanHA, OkoloPI, MullinG, et al.Liquid gastric emptying is often abnormal when solid emptying is normal. J Clin Gastroenterol2009;43:639. CrossRef

35. ZiessmanHA, ChanderA, RamosA, et al.The added value of liquid gastric emptying compared to solid emptying alone. J Nucl Med2009;50:726. CrossRef

36. SachdevaP, MalhotraN, PathikondaM, et al.Gastric emptying of solids and liquids for evaluation of gastroparesis. Dig Dis Sci2011;56:1138. CrossRef

37. Von der OheMR, CamilleriM. Measurement of small bowel and colonic transit: indications and methods. Mayo Clin Proc1992;67:1169. CrossRef

38. BonapaceES, MaurerAH, DavidoffS, et al.Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. Am J Gastroenterol2000;95:2838. CrossRef

39. ZuckierLS. Acute gastrointestinal bleeding. Semin Nucl Med2003;33:297. CrossRef

40. SfakianakisGN, HaaseGM. Abdominal scintigraphy for ectopic gastric mucosa: a retrospective analysis of 143 cases. Am J Roentgenol1982;138:7. CrossRef

41. ShynPB. 18 F‐FDG positron emission tomography: potential utility in the assessment of Crohn's disease. Abdom Imaging2012;37:377. CrossRef

42. HoltmannMH, UenzenM, HelishchA, et al.18F‐Fluorodeoxyuglucose Positron‐Emission Tomography (PET) can be used to assess inflammation non‐invasively in Crohn's disease. Dig Dis Sci2012;57:2658. CrossRef

43. KrenningEP, KwekkeboomDJ, BakkerWH, et al.Somatostatin receptor scintigraphy with 111 In‐DTPA and I‐123 octreotide. The Rotterdam experience with more than 1000 patients. Eur J Nucl Med1993;20:716. CrossRef

44. LebtahiR, CadiotG, SardaL, et al.Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med1997;38:853.

45. (a) DelbekeD, MartinWH. Pet and PET‐CT for the evaluation of colorectal carcinoma. Semin Nucl Med2004;35:84.(b) WhitefordMH, WhitefordHM, YeeLF, et al.Usefulness of FDG‐PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and recturm. Dis Colon Rectum2000;43:759.

47. (a) HuebnerRH, ParkKC, ShepherdJE, et al.A meta‐analysis of the literature for whole body FDG PET detection of colorectal cancer. J Nucl Med2000;41:1177.(b) KinkelK, LuY, BothM, et al.Detection of hepatic metastases from canceers of the gastrointestinal tract by using noninvasive imaging methods: a meta‐analysis. Radiology2002;224:748.(c) FlamenP, LerutA, Van CutsemE, et al.Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol2000;18:3202.

50. WeberWA, OttK, BeckerK, et al.Preiction of response to preoperative chemotherapy in adenocarcinomas of esophaphogastric junction by metabolic imaging. J Clin Oncol2001;19:3058.

51. AntochG, KanjaJ, BauerS, et al.Comparison of PET, CT, and dual‐modality PET/CT imaging for monitoring of Imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med2004;45:357.

52. DelbekeD, PinsonCW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg2004;11:4. CrossRef

53. DiederichCG, StaibL, GlattingG, et al.FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med1998;39:1010.

54. GambhirS, CzerninJ, SchwimmerJ, et al.A tabulated summary of the FDG PET literature. J Nucl Med2001;42:S1.

55. StroobantsS, GoeminneJ, SeegersM, et al.18FDG poitron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivac). Eur J Cancer2003;39:2012. CrossRef